New & Improved!

Submit a New & Noteworthy
November 2018
Butalbital Acetaminophen Capsule
By: Mayne Pharma (USA) Inc

Butalbital Acetaminophen Capsule

Mayne Pharma Group announces the launch of the butalbital acetaminophen (APAP) capsule 50 mg/300 mg in the United States. This is a new capsule formulation of butalbital/APAP, which is indicated for the treatment of tension headache (migraine). Complementary to Mayne Pharma’s butalbital/APAP tablet 50 mg/300 mg, this capsule formulation provides alternative treatment choices for patients who previously only had a tablet option. The company expects several product launches within the coming year, with 14 drug applications pending US FDA approval.

Mayne Pharma (USA) Inc

Click here to view product detail on Findit.

Current Issue

Enter our Sweepstakes now for your chance to win the following prizes:

    Just answer the following quick question for your chance to win:

    To continue, you must either login or register:

    As of May 24, 2018, www.pppmag.com's Terms of Use and Privacy Policy have been updated.
    You can review the Terms of Use HERE and the Privacy Policy HERE.
    By continuing to use www.pppmag.com, you are agreeing to these changes.